Phospho-Tau (thr 175)

Tauopathies are a group of diverse dementias and movement disorders which have a common pathological feature in that they all display the presence of intracellular accumulation of abnormal filaments of tau protein. Furthermore, these accumulated tau proteins all display an abnormal phosphorylation pattern that may be disease specific. As an example, Amyotrophic lateral sclerosis (ALS, also referred to as Charcot’s disease or Lou Gehrig’s disease) is the most common form of progressive motor neuron disease in North America. ALS gradually disables the patient’s voluntary motor muscle control until it becomes fatal.

Peptide phosphorylated at Thr 175

The antibody recognizes the human Phospho-Tau protein peptide at the Threonine 175 (Thr 175) phosphorylation site. (MW 48-67 kDa)

---

None

Immunogen affinity purified, stored in PBS pH7.4 and lyophilized.

If reconstituted with deionized water in 50 µL: WB: 1:10000; IHC 1:1000. Optimal dilution has to be determined by the user.

Research Use Only

Lyophilized antibodies can be kept at 4ºC for up to 3 months and should be kept at -20ºC for long-term storage (2 years). To avoid freeze-thaw cycles, reconstituted antibodies should be aliquoted before freezing for long-term (1 year) storage (-80ºC) or kept at 4ºC for short-term usage (2 months). For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made with the assay buffer. After the maximum long-term storage period (2 years lyophilized or 1 year reconstituted) antibodies should be tested in your assay with a standard sample to verify if you have noticed any decrease in their efficacy. To limit antibody loss or degradation, BSA (final concentration 1%) and sodium azide (final concentration 0.02%) can be added to the suggested first dilution. It is important to first verify if those preservatives are compatible with your assay.